current data on rcc therapy: sunitinib dosing, combination therapy and more
Published 3 years ago • 45 plays • Length 6:19Download video MP4
Download video MP3
Similar videos
-
6:26
current data on rcc therapy: sunitinib dosing, combination therapy and more
-
4:00
dosing and combinations of sunitinib vis-à-vis alternative therapies for rcc
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
7:29
alternative scheduling of sunitinib and newer therapies for rcc: an update from asco 2017
-
6:57
dosing schedule of sunitinib in renal cell carcinoma
-
4:55
current concepts in initial and adjuvant rcc treatment
-
1:01
dr. jonasch on alternative sunitinib scheduling for mrcc
-
1:25
dr. tannir on the combination of sunitinib and temsirolimus for metastatic renal cell carcinoma
-
5:09
comparz trial and alternate sunitinib dosing schedule in metastatic renal cell carcinoma
-
4:57
sunitinib or pd-1 as frontline rcc therapy: a conceptual review
-
4:51
sunitinib or pd-1 as frontline rcc therapy: a conceptual review
-
9:30
study on avelumab and axitinib vs sunitinib in the treatment of advanced renal cell carcinoma
-
5:54
adjuvant sunitinib’s role in the treatment of rcc
-
1:24
dr. figlin on sunitinib for patients with rcc
-
2:23
s-trac phase iii trial of sunitinib as adjuvant therapy in high-risk renal cell cancer patients
-
7:14
dosing sunitinib and pazopanib in renal cell carcinoma
-
7:04
sunitinib 4/2 vs 2/1 schedule for patients with mrcc
-
7:18
vegf tki therapy in the adjuvant setting of rcc